The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The Medical Advertising Hall of Fame honored 2019 inductees Carol DiSanto and Charlene Prounis on Feb. 7th at The Pierre in New York City.
Leadership representing the 2018 Manny Award agency and network winners and finalists share their views on various healthcare industry trends and developments.
Less than 8 percent of respondents to a research study of clinical trial participants felt that the potential negative consequences of data sharing outweighed the benefits.
For this 32nd annual special report, Med Ad News editors rank and profile the world’s top 50 companies that generate revenue from healthcare products.
From 2014 through year-end 2017, Amgen delivered $1.5 billion in transformation and process improvement savings that the company has reinvested in launching new medicines, advancing the product pipeline, and pursuing external business development opportunities.
GlaxoSmithKline management has embarked on the start of a new approach to R&D that aims to capitalize on the company’s assets within a promising early-stage pipeline.
The executive management team of this “132-year-old startup” company is excited about a future that lies beyond the intersection of science and technology.
The long-term strategy of Novartis is concentrated on becoming a leading medicines company powered by data and digital.